Juniper Pharma (NASDAQ: JNP) reported Q4 EPS of ($0.19), $0.17 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $7.89 million and $7.3 million last year.

“2015 was a transformative year for Juniper, with strong performance in every aspect of our business,” stated Frank Condella, Chief Executive Officer. “We made significant progress in R&D, advancing COL-1077 10% lidocaine vaginal gel into the clinic as a promising anesthetic for pain associated with minimally-invasive gynecologic procedures. We look forward to reporting results from this 185-patient randomized, double-blinded Phase 2b study in the third quarter.

“Another important 2015 event was securing the global license to a novel segmented intravaginal ring (IVR) that holds great potential to profoundly improve the delivery of therapeutics to women. Our initial IVR product candidates are designed to better address the needs of women suffering from overactive bladder and the symptoms of menopause, and for the prevention of preterm birth. “We are well positioned to fully fund our 2016 operations and planned R&D activities with cash flow from our base business and cash on hand. With successful execution of our current operating plans, we can potentially launch three new products within the next five years with a combined market opportunity well over $1 billion,” Condella concluded.

Liquidity

Cash and cash equivalents were $13.9 million as of December 31, 2015, versus $16.8 million at December 31, 2014, largely due to changes in working capital.

Financial Outlook

Juniper expects modest revenue growth in 2016 as the strong U.S. Dollar continues to have a negative translation impact on our service and ex-U.S. CRINONE revenue despite strong in-market growth for those businesses. Juniper is positioned to fund 2016 operations and planned R&D activities from cash flow generated by core business operations and our existing cash position.

For earnings history and earnings-related data on Juniper Pharma (JNP) click here.